BLZ-945
| Code | Size | Price |
|---|
| AG-CR1-3609-M001 | 1 mg | £45.00 |
Quantity:
| AG-CR1-3609-M005 | 5 mg | £90.00 |
Quantity:
| AG-CR1-3609-M025 | 25 mg | £310.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
BLZ945
Appearance:
Pale yellow solid.
CAS:
953769-46-5
EClass:
32160000
Form (Short):
liquid
Hazards:
H302, H312, H319, H332
InChi:
InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1
InChiKey:
ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Long Description:
Chemical. CAS: 953769-46-5. Formula: C20H22N4O3S. MW: 398.5. Anticancer compound. Orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R; c-Fms) inhibitor. More than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and platelet-derived growth factor receptor beta (PDGFRbeta). Selective against more than 200 additional kinases.
MDL:
MFCD28142668
Molecular Formula:
C20H22N4O3S
Molecular Weight:
398.5
Package Type:
Vial
Precautions:
P261, P280, P301, P312, P302, P352, P304, P340
Product Description:
Anticancer compound. Orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R; c-Fms) inhibitor. More than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and platelet-derived growth factor receptor beta (PDGFRbeta). Selective against more than 200 additional kinases [2].
Purity:
>95%
SMILES:
CNC(=O)C1=CC(OC2=CC=C3N=C(N[C@@H]4CCCC[C@H]4O)SC3=C2)=CC=N1
Solubility Chemicals:
Soluble in DMSO. Slightly soluble in ethanol. Insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011) | CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013) | CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013) | Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013) | Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
Related Products
| Product Name | Product Code | Supplier | Altenusin | AG-CN2-0143 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|